Dublin-headquartered Alkermes (Nasdaq: ALKS) has announced new long-term data from a Phase III trial of Lybalvi (olanzapine/samidorphan).
The therapy is approved for the treatment of schizophrenia and bipolar I disorder in the USA, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes.
The topline data show that 35.9% of participants completed the four-year treatment period, and safety results were consistent with previous studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze